Rx: Your Daily Dose — The Price Tag on a Pill: Trump's MFN Drug Deals vs. The Clinical Reality

The Trump administration just expanded its "most-favored-nation" drug pricing initiative, bringing the total number of companies to 26 after securing agreements with nine mid-cap biotechs including Teva, CSL, and BridgeBio. The move signals that the White House is serious about leveraging Medicaid's purchasing power to align U.S. drug costs with European counterparts. However, experts warn that Medicaid already gets deep discounts, meaning these deals might...